- Fordham University, J.D. (1990)
- Columbia University, B.S. in Mechanical & Chemical Engineering (1983)
- Stanford University, Certificate in Genetics and Genomics (2017)
- New York State Bar
- District Court for the Southern District of New York
- U.S. Court of Appeals for the Federal Circuit
- U.S. Patent & Trademark Office (No. 47,039)
- Of Counsel, Locke Lord, LLP, New York (2014-2017)
- Associate General Counsel, Hi-Tech Pharmacal Co. Inc., Amityville, N.Y. (2008-2014)
- Counsel, Kaye Scholer, LLP New York (1990-2008)
- Software Engineer, Singer-Kearfott, New Jersey (1983-1987)
Representative Patent Litigation Experience
- Allergan, Inc. v. Apotex, Inc., et al. (Latisse®, bimatoprost 0.03%
Represented defendant Hi-Tech Pharmacal at trial and appeal. Federal Circuit held that Allergan's method of treatment patents are invalid. 754 F.3d 952 (Fed. Cir. 2014)
- Allergan, Inc. v. Sandoz Inc., et al. (Lumigan®, bimatoprost 0.01%
Represented defendant Hi-Tech Pharmacal. District court held that asserted formulation and method patents are valid and infringed. Affirmed on appeal to the Federal Circuit.
- Senju Pharmaceutical et al. v. Lupin et al. (Gatifloxacin, Zymar®/Zymaxid®
Represented defendant Hi-Tech Pharmacal. Settled asserted polymorph patent; district court held asserted formulation patent invalid. Affirmed on appeal to the Federal Circuit.
- Pfizer Inc. v. Synthon (Norvasc®, amlodipine
Represented Pfizer, Inc. District court held that salt patent valid and infringed. Federal Circuit reversed and held patent invalid.
- Omega Engineering v. Raytek Corp.
Represented Omega in jury trial, resulting in finding of infringement by Raytek and awarding $24 million to Omega in damages. (D. Con. 3:98 CV 733)
- Pfizer Inc. v. Andrx (Glucotrol® XL
Represented Pfizer Inc. regarding osmotic sustained release patents. Case settled.
- Upjohn Co. v. Mova Pharm. (Glynase®)
Represented Upjohn Co. in formulation patent lawsuit. Federal Circuit held patent valid and enforceable, but not infringed. 225 F.3d 1306 (Fed. Cir. 2000).
- Pfizer, Inc. v. Zenith Goldline (Zoloft®, Sertraline
Represented Pfizer, Inc. in lawsuit asserting polymorph and formulation patents. (D. N.J. CA 00CV408). Case settled.
- Bayer and Pfizer v. Mylan, Biovail and Martec (Procardia® XL, Adalat® CC, nifedipine)
Represented Pfizer in sustained release formulation and particle size patents against generics.
Recent PublicationsLocke Lord QuickStudy: Direct Infringement Prong of 35 U.S.C. § 271(b) in a Hatch-Waxman Case May Be Satisfied When the Prescribing Physician Directs or Controls Acts of Patients
Locke Lord Publications Locke Lord LLP January 25, 2017
After ‘Halo’ and ‘Octane Fitness’: Are Patent Opinions Again Necessary?
New York Law Journal October 6, 2016
Objective Reasonableness Still Relevant Post-Halo
Law360 September 29, 2016
Locke Lord Article: Effect of Amendments to Federal Rules or Civil Procedure In Patent Infringement Cases
Locke Lord Publications December 9, 2015